Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT by Kawut, Steven M. et al.
Rationale and design of a Phase II clinical trial of aspirin and
simvastatin for the treatment of pulmonary arterial hypertension:
ASA-STAT
Steven M. Kawut, MD, MSa,b,c, Emilia Bagiella, PhDd, Daichi Shimbo, MDe, David J.
Lederer, MD, MSe, Nadine Al-Naamani, MDe, Kari E. Roberts, MDf, R. Graham Barr, MD,
DrPHe,g, Wendy Post, MD, MSh, Evelyn Horn, MDi, Russell Tracy, PhDj, Paul Hassoun,
MDh, and Reda Girgis, MB, BChh for the ASA-STAT Study Group
a Penn Cardiovascular Institute, University of Pennsylvania School of Medicine, Philadelphia, PA
b Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA
c Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of
Medicine, Philadelphia, PA
d Department of Biostatistics, Joseph L. Mailman School of Public Health, Columbia University,
New York City, NY
e Department of Medicine, College of Physicians and Surgeons, Columbia University, New York
City, NY
f Department of Medicine, Tufts School of Medicine, Boston, MA
g Department of Epidemiology, Joseph L. Mailman School of Public Health, Columbia University,
New York City, NY
h Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
i Department of Medicine, Cornell-Weill Medical Center, New York City, NY
j Department of Laboratory Medicine, University of Vermont School of Medicine, Burlington, VT
Abstract
Background—Pulmonary arterial hypertension (PAH) is a progressive disease which causes
exercise limitation, heart failure, and death. Aspirin and simvastatin are highly effective and safe
therapies for other cardiovascular diseases characterized by platelet activation and endothelial
dysfunction, but have not been formally studied in PAH.
Methods—ASA-STAT is a Phase II, randomized, double-blind, placebo-controlled 2 × 2
factorial clinical trial of aspirin and simvastatin in patients with PAH. A total of 92 subjects were
to be randomized to aspirin or aspirin placebo and simvastatin or simvastatin placebo. The primary
outcome is the distance walked in six minutes at six months after randomization. Secondary
measures include brachial artery flow-mediated dilation, circulating biomarkers of platelet and
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endothelial function, functional class, quality-of-life, and time to clinical end points. The incidence
of adverse events will be compared between treatment groups.
Screening and Enrollment—We screened a total of 712 individuals with PAH. Sixty-five
subjects were enrolled when the trial was terminated for futility in reaching the primary end point
for simvastatin.
Conclusions—This study aims to determine whether aspirin or simvastatin have beneficial
biologic or clinical effects in patients with PAH. The safety and side effects of these commonly
prescribed cardiovascular drugs will also be assessed.
Keywords
Pulmonary hypertension; Endothelial dysfunction; platelets; Clinical trial
Background
Pulmonary arterial hypertension (PAH) includes idiopathic (IPAH) and heritable forms, as
well as PAH associated with connective tissue disease, portal hypertension, anorexigen use,
HIV infection, congenital systemic-to-pulmonary shunts, and other comorbidities. In PAH,
the small muscular pulmonary arteries show endothelial proliferation and smooth muscle
hypertrophy, in situ thrombosis, and plexiform lesions. Right ventricular failure ensues,
leading to exercise limitation and death.
Reduced prostacyclin (PGI2) production, elevated endothelin-1 (ET-1) levels, and deficits in
nitric oxide (NO) have invited interventions which have proven effective in PAH. Platelet
activation, endothelial nitric oxide synthase (eNOS) dysfunction, oxidative stress, and
inflammation have not been specifically targeted however. Activated platelets metabolize
arachidonic acid via cyclooxygenase (COX), producing thromboxane (Tx) A2 which causes
platelet aggregation, vasoconstriction, and vascular smooth muscle hypertrophy. Patients
with PAH have increased TxA2 production and decreased PGI2 production, even with
treatment. 1, 2 Thrombocytopenia due to platelet trapping in the lungs occurs during PAH
“crises”3, 4 and is associated with worse hemodynamics.5 Aspirin permanently inactivates
platelet COX, lowers the TxA2/PGI2 ratio, and has clear benefit in systemic cardiovascular
disease. We have shown that aspirin potently inhibits platelet aggregation and synthesis of
Tx in PAH as well,2 offering a potential therapeutic approach through inhibition of this
maladaptive eicosanoid pathway.
NO production and eNOS activity are reduced, whereas oxidative stress is increased in
patients with PAH.6, 7 Pulmonary and systemic vascular endothelial dysfunction may
impact on symptoms and exercise performance in PAH, therefore therapies which normalize
vascular dysfunction could be effective. Statins affect vascular smooth muscle cells
(inhibition of proliferation, induction of apoptosis, vasorelaxation) and endothelial cells
(enhanced expression and activity of eNOS) and reduce oxidative stress and inflammation.
Several studies in animal models of pulmonary hypertension have demonstrated efficacy.8, 9
One randomized clinical trial in patients with PAH showed that simvastatin decreased right
ventricular mass and plasma N-terminus pro-brain natriuretic peptide (NT-proBNP), but had
no effect on six minute walk distance (6MWD) at six months.10 By targeting platelets and
endothelial dysfunction, aspirin and simvastatin have potential for the treatment of PAH.
The goals of this randomized clinical trial are to show the feasibility of studying these
“traditional” cardiovascular therapies in PAH in a National Institutes of Health-funded study
and to get estimates of efficacy and safety to guide future studies of these interventions, if
beneficial.
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ASA-STAT is a Phase II randomized, double-blind, placebo-controlled 2 × 2 factorial study
to determine the efficacy and safety of aspirin and simvastatin in patients with PAH. The
primary hypothesis is that the 6MWD at six months will be greater in subjects assigned to
active aspirin or simvastatin than to the respective placebo after adjustment for baseline
6MWD. Secondary outcomes include measures of platelet activation (serum TxB2, plasma
β-thromboglobulin (β-TG), soluble P-selectin) and endothelial function (brachial artery
flow-mediated dilation (FMD), plasma von Willebrand factor (vWF)), WHO functional
class, Borg dyspnea score, Short Form-36 (SF-36) scores, and time to clinical worsening.
Other end points include plasma NT-proBNP, plasma C-reactive protein (CRP), and the
incidence of adverse events.
The trial was designed by the PI and the co-investigators and was conducted at four Field
Centers (Appendix). The study was funded by the National Heart, Lung and Blood Institute
(NHLBI). Study drugs and placebos were provided free of charge by Bayer HealthCare LLC




We initially planned to recruit 128 subjects with PAH (anticipating 100 completers) over
approximately three years. Due to slower than anticipated recruitment, the target sample size
was revised to 92 (anticipating 80 completers) in May 2009 by request of the Data and
Safety Monitoring Board (DSMB) (See below). The first patient was randomized in January
2007 and a total of 65 were randomized by September 2009, when the study was terminated
for futility of the simvastatin arm (See below).
We included patients with PAH without an indication for aspirin or statin therapy and
without risk factors for adverse events from these medications (Table 1). Study participation
included a six-month treatment period and a one-month follow-up period (Table 2).
Recruitment and randomization
The Institutional Review Board at each Field Center and an independent DSMB approved
the protocol prior to initiation of screening and recruitment.
Patients were identified by medical staff at each Field Center. At baseline, subjects were
randomly assigned in a 1:1:1:1 ratio by a Web-based computerized system to daily aspirin
81 mg/simvastatin 40 mg, aspirin 81 mg/simvastatin placebo, aspirin placebo/simvastatin 40
mg, or aspirin placebo/simvastatin placebo. The four combinations of medications were
prepackaged in numbered kits and dispensed based on the randomization number provided
by the Web-based system. The randomization scheme was permuted block randomization,
stratified by type of PAH (idiopathic/heritable vs. other) and center. All study personnel
(other than the Data Coordinating Center (DCC) Chair) were masked to treatment
assignment, and masking was not broken until all study assessments were completed.
Trial organization
The ASA-STAT Executive Committee was responsible for all aspects of the study (See
Appendix). The DCC is based at Columbia University. There are four Field Centers
(Columbia University, Johns Hopkins University, University of Pennsylvania, and Tufts
Medical Center). The Ultrasound Core Laboratory and the Exercise Core are based at
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Columbia University. Blood biomarker assays are being performed at the Laboratory Core at
the University of Vermont. An Endpoint Adjudication Committee will review all bleeding
events, hospitalizations, and deaths. The trial is registered at clinicaltrials.gov
(NCT00384865)
Study drugs
Enteric-coated aspirin 81 mg (Tiny Tablets) and matching placebo were supplied by Bayer
HealthCare LLC. Simvastatin 40 mg (Zocor) and matching placebo were supplied by Merck
& Co., Inc.
Major bleeding assessed by the investigators warranted permanent discontinuation of the
aspirin/placebo study medication, but the simvastatin/placebo medication was continued as
were study assessments. Severe or acute anemia and INR > 5.0 warranted interruption of
aspirin study drug. A new absolute indication for anti-platelet therapy or statin therapy
required discontinuation of both study medications. Persistent elevations in CPK or with
symptoms mandated cessation of the simvastatin study drug. Management for increased
transaminases depended on whether the subject was also receiving an endothelin receptor
antagonist.
If surgical or other invasive procedures warranted temporary discontinuation of aspirin/
aspirin placebo, the medication was reinstituted after the procedure according to usual
clinical practice. Study drugs were not interrupted for serious adverse events which were not
drug-related. Even with permanent discontinuation of one or both study medications,
participants were strongly urged to complete all scheduled study visits and assessments.
Upon termination of the trial, the DSMB recommended and the NHLBI mandated stopping
all study medications of active subjects.
Outcome measures and data collection
The schedule of assessments is presented in Table 2. Each subject had study visits at
baseline, six weeks, three months, and six months. There were telephone calls at 1 month,
4.5 months, and 7 months from baseline. At screening, a Research Coordinator provided the
subject with a Medication Diary, which included a section for notation of new “as needed”
medications or medication changes and a list of generic and trade names of non-steroidal
anti-inflammatory drugs (NSAID)/aspirin-containing drugs. The Research Coordinator
provided instructions regarding the avoidance of aspirin and NSAIDs and smoking for 14
days prior to the Baseline Visit and throughout the trial.
The Research Coordinator called the study subject 1-2 days before each study visit remind
him or her: 1) to not eat or drink (except water) for twelve hours before the study visit, 2) to
not exercise heavily in the twelve hours before the study visit, 3) to bring all medications
with him or her to the study visit, 4) to bring the Medication Diary, 5) to wear loosely fitting
clothing and comfortable walking shoes, and 6) to remind her/him where to go for the study
visit.
All subjects underwent evaluation at each study day in the following order, beginning in the
early morning: phlebotomy, brachial artery ultrasound, light snack (if desired by the patient),
detailed history and physical examination, completion of the SF-36 questionnaire, and six
minute walk test (performed > one hour after a light snack).
Biological samples
Phlebotomy was performed using a standardized methodology and minimal tourniquet
technique. Study staff presented to Field Center personnel information relating to the
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standardized collection of blood samples and proper processing procedures for the array of
draw tubes and certified them for quality assurance (QA). Blood was centrifuged and
plasma, serum, and cells were stored at −70°C. One phlebotomy and sample processing
procedure was observed by central study staff every six months for quality controls (QC).
Flow-mediated dilation (FMD)
Brachial artery ultrasound measures peripheral vascular NO-dependent FMD after transient
ischemia. Lower FMD predicts an increased risk of cardiovascular events and death in
disease-free participants and congestive heart failure,11, 12 and interventions which increase
FMD improve outcomes.13, 14 In brief, a blood pressure cuff is placed on the forearm, and a
baseline rest image of the brachial artery is acquired. Then, inflation of the cuff above
systolic pressure causes artery occlusion; forearm ischemia results in downstream vessel
dilation. Cuff deflation produces a brief high-flow state (reactive hyperemia) to
accommodate the dilated vessels. The resulting increase in shear stress on the brachial artery
endothelium produces FMD, expressed as % increase in artery diameter.
Image acquisition was performed according to a standard protocol at three Field Centers
(Columbia University, Johns Hopkins University, and Tufts Medical Center). Two trained
readers at the Ultrasound Core will interpret the studies using Vascular Tools (Version 5.05)
(Medical Imaging Applications). We will compare FMD at one minute after cuff deflation,
maximal FMD, and baseline vessel diameter between treatment groups. All
ultrasonographers underwent a one day training session at Columbia University and
submitted five mock studies for review for QA. QC measures included having the
supervising physician observe a study performed for ASA-STAT every six months at each
Field Center. For assessment of reliability, the ultrasonographers performed mock studies on
a volunteer on two sequential days every six months.
WHO functional class
The WHO functional classification for PAH has been modified from the well-known New
York Heart Association functional classification, with Class I being defined by no
symptoms, Class II as symptoms with more than usual activity, Class III as symptoms with
less than usual activity, and Class IV with symptoms at rest.
Addition of PAH medication or increased doses of current PAH therapies
The addition of new therapy for PAH or dose increase indicates disease worsening. Often,
clinicians will increase medication dose with clinical worsening (specifically, PGI2 analog
therapy). PAH medication additions and dose changes will therefore be analyzed as a
secondary end point.
SF-36
The SF-36 is a widely used measure of subjective health status and includes one multi-item
scale that assesses eight health concepts: 1) limitations in physical activities because of
health problems; 2) limitations in social activities because of physical and emotional
problems; 3) limitations in usual role activities because of physical health problems; 4)
bodily pain; 5) general mental health; 6) limitations in usual role activities because of
emotional problems; 7) vitality; and 8) general health perceptions.
Six-minute walk distance (6MWD)
The primary outcome of the study is the 6MWD at six months after adjustment for the
baseline 6MWD. The 6MWD is considered an intermediate end point in PAH and has
served as the primary end point for virtually every Phase III clinical trial in PAH. Study staff
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trained the technicians at the Field Centers responsible for conducting the unencouraged six
minute walk test. QA consisted of a lecture and demonstration of the methodology and
certification of each technician after he or she performed an acceptable test on a mock
subject. For QC, ASA-STAT clinical coordinating staff observed one ASA-STAT patient
performing the six minute walk as a part of a study visit at each Field Center every six
months.
Laboratory analyses
Platelets and endothelial cells release several substances upon activation and dysfunction/
injury, respectively; inflammation and cardiac dysfunction result in the release of other
circulating biomarkers. P-selectin (CD-62P) is a glycoprotein expressed on the platelet
surface during activation and shed into the plasma. Patients with PAH have increased
soluble P-selectin levels, which correlate with pulmonary vascular resistance and decrease
after aspirin administration or chronic epoprostenol therapy.2, 15 Soluble P-selectin will be
measured using an ELISA (R & D Systems).
In platelets, eicosanoid metabolism mostly produces TxA2, which is rapidly metabolized to
the more stable TxB2, which will be measured in serum using ELISA (Cayman Chemical) .
β-TG is released upon platelet activation and will be measured using an ELISA
(Asserachrom B-TG, Diagnostica Stago, Inc.)
Plasma vWF is a large multimeric glycoprotein which is released by endothelial injury. vWF
will be measured using an immunoturbidimetric assay (Diagnostica Stago, Inc.). Plasma
CRP levels will be measured using a nephelometric assay (Siemens BNII). Plasma NT-
proBNP will be measured using a chemiluminescent immunometric assay (Roche Elecsys
2010).
Hospitalization for right-sided heart failure
We recorded all hospitalizations during the study. Records from each hospitalization are
reviewed by the Endpoint Adjudication Committee. A hospitalization because of lower
extremity edema or dyspnea refractory to outpatient increases in dose or frequency of
diuretics or specific PAH medications will be considered a right-sided heart failure
hospitalization. Hospital admissions that do not meet this definition will be considered non-
right-sided heart failure hospitalizations.
Other clinical endpoints
Clinically significant events, such as atrial septostomy, lung transplantation, or death, will
be recorded. Cardiovascular death will be defined as: 1) sudden death or 2) death preceded
by: a) cardiogenic shock (hypotension resulting in a failure to maintain normal renal or
cerebral function for >15 minutes prior to death) or b) heart failure symptoms or signs
requiring intravenous therapy or oxygen in the hospital or confinement to bed, in the
absence of secondary causes (such as systemic infection or dysfunction of intravenous or
subcutaneous medication delivery devices) or alternative causes of death. Other deaths will
be considered non-cardiovascular deaths.
Major and minor bleeding will be assessed. A major bleeding episode is defined as: 1)
symptomatic bleeding in a critical area or organ (e.g., intracranial, intraspinal, intraocular,
retroperitoneal, intraarticular, or intramuscular with compartment syndrome), 2) overt
bleeding causing a fall in hemoglobin level of ≥ 2 g/dl or requiring surgery or transfusion, or
3) bleeding resulting in permanent functional disability or death. A minor bleeding episode
is bleeding which does not meet any of the preceding criteria. All potential endpoints
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(bleeding, hospitalization, death) will be evaluated by the Endpoint Adjudication Committee
which is blinded to study medication and other information regarding study subjects.
Adherence
Study staff instructed each subject to check a box in the Medication Diary when he or she
took each of his study medications for each day. If medications were held or not taken for
any reason, the subject left the box empty and made a brief notation for why one, the other,
or both medications were not taken.
Statistical considerations
As a Phase II study, the main goals are to assess safety and side effect profiles of aspirin and
simvastatin in PAH and to provide initial effect estimates of efficacy for use in designing
larger Phase III trials.
The primary end point of the trial is the 6MWD at six months after randomization after
adjustment for the baseline 6MWD. Preliminary data suggested that a difference of > 50 m
in 6MWD was associated with an improvement in symptoms and survival. A total of 100
subjects (25 in each of the four randomized groups, 50 in each active drug and placebo
group) was necessary to detect a difference of 57 m with 80% power assuming no
significant interaction between study drugs and without adjustment for the baseline 6MWD.
Anticipating 20% attrition, we initially planned for the enrollment of 128 subjects. With a
significant interaction between study medications, we had 80% power to detect a difference
of 80 m.
In May 2009, the DSMB requested revised sample size calculations using the correlations of
baseline and six month 6MWD thus far in the trial and from other sources and using an
attrition rate closer to that seen in the trial to that point. With a correlation coefficient
between baseline and six-month 6MWD ≥ 0.60, we had 80% power to detect a 57 m
difference in 6MWD after adjustment for baseline 6MWD with 80 completers in the absence
of a significant interaction between study medications. Using the approximate completion
rate in the study, 92 subjects were deemed necessary. With an interaction, there was 80%
power to detect an 82 meter difference using the same assumptions. The revised sample size
of 92 was approved by the DSMB and NHLBI on June 4, 2009.
Data analysis
Eligible patients were randomized in equal proportion to one of four possible treatment
assignments (Figure 1). Patients were stratified at randomization by Field Center and type of
PAH. The primary analysis will proceed according to the intent-to-treat principle, including
all randomized participants regardless of their compliance with the study treatment or
follow-up schedule. Hypothesis testing for the primary and secondary endpoints will be
conducted using two-sided α = 0.05.
The treatment groups will be compared at baseline with respect to demographics. We will
characterize subjects with regard to baseline and follow-up 6MWD, FMD, biomarker levels,
and other outcome measures as well as absolute and percentage change between the baseline
and six-month assessments.
A very important aspect of a factorial trial is the assessment for an interaction between the
two study treatments. As this Phase II trial was not powered for formal statistical testing for
an interaction, we will construct 95% confidence intervals for the interaction term for study
drugs for each analysis.16 If the upper bound of this confidence interval for this interaction
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term exceeds a clinically relevant effect size, we will consider a significant interaction to be
present for those analyses.
The primary analysis will compare the absolute measurement of each primary and secondary
endpoint at six month follow-up between active therapy and placebo groups while adjusting
for the baseline value. We will use linear regression models for the analysis of the outcome
measures with treatment assignment as the independent variable of interest and the endpoint
as the dependent variable. If there is no interaction between the study medications, bivariate
analyses will proceed “at the margins” by comparing patients assigned to simvastatin
compared to those who were not (AS + S0 vs. A0 + 00) and patients assigned to aspirin to
those who were not (AS + A0 vs. 0S + 00) for each end point (Figure 1). If a significant
interaction exists, we will include an aspirin × simvastatin interaction term in the models.
Multiple imputation will be used for missing data for the primary end point. Exploratory
analyses will be performed incorporating all of the endpoint assessments (baseline, six
weeks, three, and six months) in linear mixed-effects models.
We will assess time to failure (as defined by the addition of new therapies or previously
stable PAH therapy dose increases, hospitalization for right-sided heart failure, lung
transplantation, atrial septostomy, and cardiovascular and all-cause death) using Kaplan-
Meier curves and Cox proportional hazards models. Patients will be censored if they have
not experienced any of the events of interest at the end of the study period. There were no
interim analyses or stopping rules planned a priori for the trial.
Time-line and trial enrollment
The enrollment period lasted from January 2007 to September 2009. In July 2009, the
DSMB requested a conditional power calculation by the DCC using the subjects enrolled
and it was determined that the trial had a 4.9% chance of detecting a statistically significant
difference in 6MWD for simvastatin vs. simvastatin placebo.17, 18 The DSMB determined
that continuing the study with only the aspirin vs. aspirin placebo comparison would lead to
a study with low scientific credibility and could not be justified, and the DSMB
recommended termination for futility. The DSMB recommended that subjects currently in
the trial (N = 16) should discontinue receiving all study drugs and should not be followed or
exposed to any additional study procedures after the date of termination (September 25,
2009). Therefore, active subjects stopped study medications and did not return to the Field
Centers or have telephone follow-up as of that date. The DSMB reported that there were no
significant safety concerns related to the recommendation for termination. The NHLBI
accepted these recommendations.
There were 712 PAH patients screened during the enrollment period (Figure 2). Treatment
with statins was the reason for exclusion in 155 of patients. Other reasons for non-eligibility
included aspirin use in 41 and pulmonary function tests not meeting inclusion criteria (or
unavailable) in 241. Those enrolled were somewhat younger, but similar in terms of gender
and race, to those screened and not enrolled (Table 3).
Summary
ASA-STAT is a multi-center, Phase-II, randomized, placebo-controlled 2 × 2 factorial trial
of aspirin and simvastatin in PAH. This study is designed to 1) explore the feasibility of
performing an NIH-funded clinical trial in PAH, 2) find treatment-related effect sizes of
aspirin and simvastatin on clinical endpoints in order to plan a Phase III trial, and 3) study
the effects of these therapies on platelet and endothelial function.
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Table 1
Inclusion and exclusion criteria
Inclusion criteria
• Previous documentation of mean pulmonary artery pressure of > 25 mm Hg at rest with a pulmonary capillary wedge pressure < 16
mm Hg (or left ventricular end-diastolic pressure < 16 mm Hg) at any time before study entry.
• Diagnosis of PAH which is a) idiopathic, b) heritable, or c) associated with: connective tissue disease, HIV infection, congenital
systemic-to-pulmonary shunt, or former anorexigen use.
• Most recent pulmonary function tests showing FEV1/FVC >50% AND either a) total lung capacity > 70% predicted or b) total lung
capacity between 60% and 70% predicted with no more than mild patchy interstitial lung disease on high resolution computerized
tomography.
• Ability to perform six minute walk testing without limitations in musculoskeletal function or coordination.
• Negative pregnancy test (women of childbearing potential) at screening.
• Use of medically acceptable contraceptive precautions (women).
• Informed consent.
Exclusion criteria
• Diagnosis of sickle cell disease.
• Clinically significant untreated sleep apnea.
• Left-sided valvular disease (more than moderate), pulmonary artery or valve stenosis, or ejection fraction < 45% on
echocardiography.
• Hospitalized or acutely ill.
• Renal failure (creatinine ≥ 2.0).
• Initiation of PAH therapy within three months of enrollment.
• Allergy or hypersensitivity to aspirin or simvastatin administration.
• Absolute indication for aspirin or other anti-platelet therapy.
• Current treatment with statin therapy.
• Inability to avoid non-steroidal anti-inflammatory medications for six months.
• Current or recent use or planned treatment with: amiodarone, cyclosporine, itraconazole, ketoconazole, erythromycin,
clarithromycin, HIV protease inhibitors, nefazodone, cimetidine, danazol, large quantities of grapefruit juice, verapamil, fibrates or
niacin.
• Peptic or duodenal ulcer diagnosed within one year.
• Gastrointestinal bleeding within six months.
• Bleeding diathesis.
• History of intracranial hemorrhage.
• Anemia (Hematocrit < 30%) at screening.
• International normalized ratio > 3.0 at screening.
• Severe thrombocytopenia (< 75,000) at screening.
• Hepatic transaminases > 2x the upper limit of normal at the center at screening.
• Chronic liver disease (cirrhosis, chronic hepatitis, etc.) with portal hypertension
• Current or recent (< 6 months) chronic heavy alcohol consumption.
• History of myositis.
• Creatine phosphokinase > 1.5x the upper limit of normal at screening.
• Abnormalities of the arm or hand or radical mastectomy (preventing assessment of flow-mediated dilation).
• Pregnant or lactating women.
• Current use of another investigational (non-FDA approved) drug for PAH.
• Lung transplant recipients.
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• Age < 18 years.
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Table 3
Screened and enrolled subjects
Screened, not enrolled* (N = 647) Eligible, enrolled (N = 65)
Age, years 55 ± 16 50 ± 14
Female gender, % 78 85
Race/ethnicity, %
 Non-Hispanic Caucasian 68 65
 Hispanic 7 14
 African-American 20 17
 Asian 4 5
 Multiracial 1 --
*
N = 16 missing age, 19 missing gender, 110 missing race/ethnicity
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